Category Archives: Guest Blog

The Wearable Technology Revolution? iWatch This Space

In the media world, it’s easy to see when a market is really taking off — someone starts a magazine or a website about it. Well, I just heard about some journalists from one of the UK’s leading gadget magazines who have headed out on their own to launch a wearable computing title. So I […]
Also posted in healthcare, Op-Ed, Technology | Tagged , , , , , | Leave a comment

Big Data in the Pharma R&D Landscape

Big Data and the mindset that comes with it will have a fundamental impact on how pharmaceutical research will be conducted in the future, writes Peter Tormay. Innovation is the corner stone of the pharmaceutical industry. Unfortunately, the industry as a whole is not very good at it. For the last two decades the approval […]
Also posted in R&D, Strategy, Technology | Tagged , , | Leave a comment

European Pharma Races to Catch Up with Data Protection

The European Union’s struggle to bring its data protection rules into the 21st century continues—haltingly—as the EU itself enters its new era, with a new European Parliament, a new President-designate of the European Commission, and a new European Commission due to take office in November. This has left the pharmaceutical sector, already out of breath […]
Also posted in Europe, Global, Technology | Tagged , , , , | Leave a comment

Is There Potential for Growth in Brazil’s Phytotherapic Drug Market?

It is well known that Brazil has an immense biodiversity and that the Amazon is the largest tropical rainforest in the world. Traditional Brazilian medicines include African elements, rooted on indigenous groups. Few pharmaceutical companies, however, know at what level phytotherapic drugs are commercialized in the country, how much regulation is imposed for herbal medicines, […]
Also posted in Emerging Markets, Global | Tagged , , , , | Leave a comment

EMA Responds Robustly to Conflict-of-Interest Claims

By Philip Ward, Applied Clinical Trials. The European Medicines Agency (EMA) has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
Also posted in Europe, Global, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta